SCHEMBL8449

SCHEMBL8449

CC1=C(C)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7981 0.78
SCHEMBL9721883 0.78 NOS3 (0.38)
SCHEMBL8560 0.78
SCHEMBL151215 0.75
SCHEMBL8461939 0.75 TRIM24 (0.38)
SCHEMBL19178734 0.75 TRIM24 (0.38)
SCHEMBL6882297 0.75 TRIM24 (0.38)
SCHEMBL8461935 0.75 TRIM24 (0.38)
SCHEMBL8461479 0.75 TRIM24 (0.38)
SCHEMBL19178733 0.75 TRIM24 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 887 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4684806-A1 FAP-TARGETED ANTIBODY-DRUG CONJUGATES Oncomatryx Biopharma, S.L. (ES) 2026-01-28 EP disclosed
EP-4663204-A1 COMPOUNDS USEFUL FOR THE MODULATION OF THE ACTIVITY OF STING Sulis Therapeutics ApS (DK) 2025-12-17 EP disclosed
EP-4663632-A1 COMPOUNDS USEFUL FOR THE MODULATION OF THE ACTIVITY OF STING Sulis Therapeutics ApS (DK) 2025-12-17 EP disclosed
WO-2025233682-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS AND USES THEREOF LIGACHEM BIOSCIENCES INC. (KR) 2025-11-13 WO disclosed
US-20250340519-A1 RADIOLABELLED COMPOUND OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2025-11-06 US disclosed
EP-4634170-A1 IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF AstraZeneca AB (SE) 2025-10-22 EP disclosed
EP-4624459-A2 RADIOLABELLED COMPOUND Oxford University Innovation Limited (GB) 2025-10-01 EP disclosed
US-12398124-B2 Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same LIGACHEM BIOSCIENCES INC. (KR) 2025-08-26 US disclosed
US-20250242043-A1 ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF LIGACHEM BIOSCIENCES, INC. (KR) 2025-07-31 US disclosed
EP-4590396-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2025-07-30 EP disclosed
US-20040192767-A1 EP4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2004-09-30 US disclosed
WO-2004080976-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2004-09-23 WO disclosed
WO-2004067524-A1 EP4 RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2004-08-12 WO disclosed
WO-2004056361-A1 4-(1-(SULFONYL)-1H-INDOL-2-YL)-4-(HYDROXY)-CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2004-07-08 WO disclosed
WO-2004052402-A1 HYPERCOILING POLYMERS AND THEIR USE IN CELLULAR DELIVERY CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) 2004-06-24 WO disclosed
WO-2004043963-A1 PYRROLOBENZODIAZEPINES SPIROGEN LIMITED (GB) 2004-05-27 WO disclosed
EP-1339716-A1 NOVEL LACTAME-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES Bayer Aktiengesellschaft (DE) 2003-09-03 EP disclosed
WO-2002042299-A1 NOVEL LACTAME-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2002-05-30 WO disclosed
US-6046350-A Tertiary alkylsilane NIPPON OIL CO., LTD. (JP) 2000-04-04 US disclosed
EP-0922706-A2 Tertiary alkylsilane NIPPON OIL CO. LTD. (JP) 1999-06-16 EP disclosed